J. Machado

Assessment of oxidative status markers and NO bioavailability in hypertensive disorders of pregnancy

G. Duarte, A. Palei, R. Cavalli, 2013, Journal of Human Hypertension.

Tissue inhibitor of matrix metalloproteinase-1 polymorphism, plasma TIMP-1 levels, and antihypertensive therapy responsiveness in hypertensive disorders of pregnancy

J. Tanus-Santos, V. Sandrim, R. Cavalli, 2014, The Pharmacogenomics Journal.

Matrix metalloproteinase-9 polymorphisms affect plasma MMP-9 levels and antihypertensive therapy responsiveness in hypertensive disorders of pregnancy PHARMACOGENOMICS

G. Duarte, R. Lacchini, L. Amaral, 2017 .

Matrix metalloproteinase-9 polymorphisms affect plasma MMP-9 levels and antihypertensive therapy responsiveness in hypertensive disorders of pregnancy

J. Tanus-Santos, V. Sandrim, R. Cavalli, 2011, The Pharmacogenomics Journal.

PP129. Assessment of oxidative status markers and no bioavailability in hypertensive disorders of pregnancy.

G. Duarte, A. Palei, R. Cavalli, 2012, Pregnancy hypertension.

PP129. Assessment of oxidative status markers and no bioavailability in hypertensive disorders of pregnancy.

J. Tanus-Santos, V. Sandrim, R. Cavalli, 2012, Pregnancy hypertension.